Sun Yize, Wang Zheyi, Wang Chao, Tang Zhuoran, Shi Jinyu, Zhao Haibin
Beijing University of Chinese Medicine.
Oriental Hospital, Beijing University of Chinese Medicine, Beijing, China.
Medicine (Baltimore). 2020 Dec 4;99(49):e23287. doi: 10.1097/MD.0000000000023287.
Recurrent angina pectoris after percutaneous coronary intervention (PCI) is a common clinical syndrome, which seriously reduces the quality of life and health of patients, increases medical costs, and causes the risk of cardiogenic death. The efficacy of various western medicine improving angina symptoms has not been fully confirmed at the moment, whereas Chinese patent medicine capsules (CPMC) have been generally used in clinical practice due to the therapeutic efficacy and safety. This study evaluates the efficacy and safety of CPMC for stable angina after PCI, designed to provide more evidence for clinical treatment.
This protocol was based on the previous reporting items. We will search 3 English databases (PubMed, Excerpta Medica Database, and the Cochrane Library) and 3 Chinese databases (China Network Knowledge Infrastructure, Wan Fang Database, and Chinese Biomedicine) until January 2020. RCTs to evaluate the efficacy and safety of CPMC for recurrent stable angina pectoris after PCI will be included. The primary outcome will be assessed by major adverse cardiovascular events and angina attack frequency. We will use the criteria provided by Cochrane risk of bias tool for quality evaluation and risk assessment, and use the Revman 5.3 for meta-analysis.
Ethical approval is not required for systematic review and meta-analysis. The results of this review will be disseminated in a peer-review journal.
CRD42020164005.
经皮冠状动脉介入治疗（PCI）后复发性心绞痛是一种常见的临床综合征，严重降低患者的生活质量和健康水平，增加医疗费用，并导致心源性死亡风险。目前，各种西药改善心绞痛症状的疗效尚未得到充分证实，而中成药胶囊（CPMC）因其治疗效果和安全性已在临床实践中普遍使用。本研究评估CPMC治疗PCI术后稳定性心绞痛的疗效和安全性，旨在为临床治疗提供更多证据。
本方案基于先前的报告项目。我们将检索3个英文数据库（PubMed、医学文摘数据库和Cochrane图书馆）和3个中文数据库（中国知网、万方数据库和中国生物医学数据库），检索截至2020年1月的文献。纳入评估CPMC治疗PCI术后复发性稳定性心绞痛疗效和安全性的随机对照试验（RCT）。主要结局将通过主要不良心血管事件和心绞痛发作频率进行评估。我们将使用Cochrane偏倚风险工具提供的标准进行质量评估和风险评估，并使用Revman 5.3进行荟萃分析。
系统评价和荟萃分析无需伦理批准。本评价结果将在同行评审期刊上发表。
PROSPERO注册号：CRD42020164005。
